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Abstract
Background and Objectives The standard of care for HIV
treatment is a three-drug regimen consisting of twonucleoside
reverse transcriptase inhibitors (NRTIs) and either a non-nu-
cleoside reverse transcriptase inhibitor, a protease inhibitor
(PI) or an integrase strand transfer inhibitor. Darunavir
boosted with ritonavir (DRV/r) is the only preferred PI in the
US Department of Health and Human Services (DHHS) HIV
treatment guidelines for antiretroviral-naı¨ve patients, recom-
mended in combination with tenofovir/emtricitabine for
antiretroviral-naı¨ve patients. For treatment-experienced and
certain antiretroviral-naı¨ve patients, abacavir and lamivudine
(ABC/3TC) in combination with DRV/r is considered an
effective and tolerable alternative, despite limited research on
the effectiveness of this particular combination. This study
evaluated virologic outcomes in treatment-experienced
patients taking ABC/3TC ? DRV/r compared to treatment-
experienced patients taking ABC/3TC with any other PI.
Methods Treatment-experienced HIV-infected patients
initiating their first regimen containing ABC/3TC in com-
bination with any PI in the year 2005 or later were selected
from the Observational Pharmaco-Epidemiology Research
and Analysis (OPERA) cohort, a prospective observa-
tional cohort reflecting routine medical care. Viral load
measurements taken during follow-up were compared
between patients taking ABC/3TC ? DRV/r and ABC/
3TC with a PI other than DRV/r. Logistic regression
models were fit to assess the association between regimen
exposure and viral load suppression.
Results A total of 151 patients initiatingABC/3TC ? DRV/
r and 525 patients initiating ABC/3TC ? a non-darunavir PI
were included. Patients in both treatment groups had com-
parable clinical indicators (viral load, CD4) at baseline. A
regimen of ABC/3TC ? DRV/r was more likely to be pre-
scribed in the later years of the study period, leading to a
shorter median follow-up in the DRV/r treatment group (as-
treated analysis: 14 vs. 17 months, p = 0.04; intent-to-treat
analysis: 33 vs. 68 months, p\ 0.001). Multivariable
logistic regression models accounting for year of regimen
initiation, among other factors, indicated no statistically
significant differences in achieving an undetectable viral
load for patients taking DRV/r with ABC/3TC compared
with other PIs, both in the as-treated (odds ratio [95 %
confidence interval]: 0.84 [0.53–1.34]) and intent-to-treat
analyses (0.82 [0.48–1.40]). Patients in both treatment
groups also showed similar reductions in viral load (median
darunavir vs. non-darunavir: -23.0 vs. -23.0 copies/mL;
p = 0.72) and gains in CD4 T cell counts (median darunavir
vs. non-darunavir: 106 vs. 108 cells/mm3; p = 0.59] while
being treated with the regimen of interest.
Conclusions Patients receiving ABC/3TC ? DRV/r
appear to experience similar treatment benefit to patients
taking ABC/3TC with other PIs in terms of achieving
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suppression, as well as absolute reductions in viral load and
CD4 lymphocyte gains.
Key Points
Darunavir boosted with ritonavir (DRV/r) paired
with abacavir and lamivudine (ABC/3TC) is
considered to be an effective and tolerable regimen
for antiretroviral treatment-experienced HIV
populations, despite little research supporting its use.
When assessed against ABC/3TC paired with other
protease inhibitors, ABC/3TC ? DRV/r is a
comparably effective regimen for achieving
virologic suppression in a real-world clinical setting.
1 Introduction
The standard of care for HIV treatment is a three-drug reg-
imen consisting of two nucleoside reverse transcriptase
inhibitors (NRTIs) and either a non-nucleoside reverse
transcriptase inhibitor (NNRTI), a protease inhibitor (PI), or
an integrase strand transfer inhibitor (INSTI) [1]. Darunavir
boosted with ritonavir (DRV/r) is the only preferred PI in the
US Department of Health and Human Services (DHHS)
treatment guidelines for antiretroviral-naı¨ve patients, rec-
ommended in combination with tenofovir/emtricitabine
(TDF/FTC). DRV/r has a high genetic barrier to the devel-
opment of resistance mutations as compared to all NNRTIs
and some INSTIs [2]. Therefore, DRV/r-containing regi-
mens may be preferred in patients who need to begin therapy
prior to resistance testing, have documented resistance to
other classes, or have issues with adherence [3].
The US Food and Drug Administration (FDA) first
approved DRV/r for use in antiretroviral-experienced
patients in 2006 [4]. Darunavir is considered to be a sec-
ond-generation PI, with a markedly better resistance profile
than older comparator PIs [5–7]. Darunavir also offers
superior potency and better short- and long-term tolera-
bility, making its use more clinically practical than many
first-generation PIs. Clinical trial data have indicated that
treatment-experienced patients receiving DRV/r are more
likely to reach and maintain treatment response when
compared with antiretroviral-experienced patients receiv-
ing other ritonavir-boosted PIs [8–10].
The most common NRTI backbone prescribed with
DRV/r is TDF/FTC. However, abacavir and lamivudine
(ABC/3TC) is considered an acceptable alternative for
certain antiretroviral-naı¨ve patients and for treatment-ex-
perienced patients. While ABC/3TC ? DRV/r is classified
as an effective and tolerable regimen according to the
current US antiretroviral therapy (ART) treatment guide-
lines [1], few studies have evaluated the effectiveness of
DRV specifically in combination with ABC/3TC. In a
retrospective study, Nishijima et al. [11] evaluated the
effectiveness of ABC/3TC ? DRV/r in 22 antiretroviral-
naı¨ve patients. Of the 18 patients who remained on the
regimen through 48 weeks, 66.7 % had a viral load of
\50 copies/mL and two patients experienced virologic
failure (two consecutive viral loads[200 copies/mL). It is
possible that the relatively low response rate observed was
due to the small sample; an analysis of larger numbers of
patients would add clarity to the issue. In a single-center,
observational pilot study, the effectiveness of ABC/
3TC ? DRV/r was compared with TDF/FTC ? DRV/r
among 80 patients with a baseline viral load of
[100,000 copies/mL [12]. No significant difference in
viral suppression or time to virologic failure at 48 weeks
was observed between the two arms. The SWIFT (Safety
and Efficacy Study of Switching from Epzicom to Tru-
vada) study was designed to evaluate switching to TDF/
FTC from ABC/3TC in patients who were on a
stable boosted PI regimen [13]. Of the 311 subjects
enrolled, only 20 were on ABC/3TC ? DRV/r and treat-
ment outcomes were not reported by individual PIs. There
is a need for additional data on the outcomes associated
with this particular regimen.
This study sought to compare the virologic and
immunologic effectiveness of ABC/3TC ? DRV/r with
ABC/3TC in combination with other PIs.
2 Methods
2.1 Study Population
The study population was selected from the Observational
Pharmaco-Epidemiology Research and Analysis
(OPERA) cohort, an observational cohort including
patients from 72 HIV specialty outpatient clinics in the
USA. In addition to demographic and medical history
information, prospectively captured details of diagnoses,
medications, and laboratory results were captured through
electronic medical records for all patients receiving
healthcare at each of these sites. All data reflect routine
medical care, with visits and testing scheduled at the dis-
cretion of the treating physicians. Information captured in
the electronic medical records system at each site was
retrieved, aggregated, and de-identified to maintain patient
confidentiality.
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Subjects for this analysis included patients in the OPERA
cohort with a documented diagnosis of HIV-1 infection. The
study population was restricted to antiretroviral-experienced
patients starting their first antiretroviral regimen containing
both abacavir and lamivudine. Patients were further restric-
ted to those initiating abacavir and lamivudine in combina-
tion with any PI after their enrollment date in the OPERA
cohort. Regimens including additional antiretroviral drugs
were excluded. Patients initiating any regimen of interest
prior to the year 2005 were also excluded. Patients were
required to have both CD4 and viral load assessments taken
during a baseline period, defined as 120 days prior to and
7 days after their ABC/3TC ? PI regimen start date, as well
as at least one viral load assessment taken prior to the end of
follow-up on this regimen. Patients were eligible for inclu-
sion regardless of virologic status at the time of initiating
their ABC/3TC ? PI regimens; both suppressed and non-
suppressed patients were evaluated together in the primary
analysis.
2.2 Study Design
Eligible patients were categorized as receiving either ABC/
3TC and DRV/r or ABC/3TC and any other PI as a third
agent. For both treatment groups, baseline was defined as
the start date for the regimen. Follow-up continued until a
patient’s last visit prior to the date of data extraction and
aggregation for analysis (6 May 2015).
The primary objective of this analysis was to compare
virologic effectiveness between the two treatment groups,
defined as achieving viral suppression below
detectable limits at any point during the follow-up period.
The threshold for classifying a viral load as unde-
tectable was assay dependent; viral load measurements
were evaluated at different laboratories over a period of
several years, leading to variable lower limits of detection
ranging from\20 to\75 copies/mL. Additional outcomes
associated with viral load were also assessed including
lowest viral load measured during follow-up and change in
viral load from baseline to the lowest copies/mL measured.
The effect of treatment on CD4 cell counts was evaluated
between treatment groups by comparing the highest CD4
count prior to end of follow-up, as well as change in CD4
counts between baseline and the highest count.
Each outcome of interest was assessed using an ‘intent-
to-treat’ analysis, where subjects remained categorized in
their initial exposure group regardless of changes to the
baseline antiretroviral regimen and were followed until
data extraction, as well as an ‘as-treated’ analysis, where
patients were followed and contributed data to their initial
exposure groups only until they changed antiretroviral
regimens or stopped receiving treatment with antiretrovi-
rals altogether.
2.3 Statistical Analysis
Baseline characteristics and certain outcome measures
were compared between the two groups using Wilcoxon
rank-sum tests for continuous variables and Chi-square
tests for categorical variables. Results were summarized as
medians with interquartile ranges (IQRs) for continuous
variables and as frequencies and proportions for categorical
variables.
Crude and multivariable logistic regression models
were fit to assess the association between regimen
exposure and viral load suppression. Separate models
were run for the ‘as-treated’ follow-up data (baseline to
end of regimen of interest) and the ‘intent-to-treat’ fol-
low-up data (baseline to the end of follow-up). Multi-
variable models were constructed using stepwise
selection methods of explanatory values. Odds ratios
(ORs) and corresponding 95 % confidence intervals
(CIs) were reported from the final unadjusted and
adjusted logistic models.
2.4 Sensitivity Analysis
In order to limit bias created by unequal amounts of follow-
up time between treatment groups, two separate sensitivity
analyses were performed. First, the study population was
limited to patients with at least 12 months of follow-up
after baseline and with a viral load assessment taken at
least 6 months after baseline. Both of these criteria were
independent of the duration of the regimen of interest.
Darunavir was approved more recently than other PIs taken
by this cohort, and regimens containing darunavir were
prescribed less frequently or not at all during the early
years of this study’s initial period. In order to account for
the potential for longer follow-up periods in patients taking
PIs other than DRV, our second sensitivity analysis
included only eligible patients initiating treatment with -
ABC/3TC ? PI in the year 2009 or later.
Treatment effectiveness was also assessed using a more
lenient threshold for the outcome of virologic control.
Rather than requiring viral load to be completely unde-
tectable, patients only had to achieve a viral load below
400 copies/mL. This outcome is referred to as suppressed
rather than undetectable.
For the primary analysis, treatment-experienced patients
were enrolled regardless of whether or not they switched to
an ABC/3TC ? PI regimen while virologically stable on a
prior ART regimen (suppressed or undetectable) or due to
treatment failure. In order to assess whether virologic status
at baseline had an impact on regimen effectiveness, results
were stratified by viral load at baseline based on a standard
threshold for defining virologic failure (B200 or
[200 copies/mL).
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3 Results
3.1 Selection of Eligible Patients
The OPERA cohort included 560,990 patients who had
data from at least one clinic visit on record (Fig. 1). Of
these patients, 58,707 had been diagnosed with HIV, with
87 % (n = 51,036) having any record of treatment with
antiretrovirals. Of those with exposure to abacavir and
lamivudine (n = 12,542), nearly half (49 %) had taken this
combination of drugs as a second-line or later regimen and
were considered antiretroviral-experienced prior to initiat-
ing the regimen of interest at baseline. Of these patients,
4128 (67 %) were prescribed their first ABC/3TC regimen
in or after the year 2005, with 3770 (91 %) of these regi-
mens occurring after entering care with an OPERA
physician. Of the patients with both baseline and follow-up
laboratory tests (n = 2122), 676 took ABC/3TC with a PI
as the third regimen agent, including 151 who took a
regimen contain ABC/3TC with DRV/r and 525 who took
a regimen containing ABC/3TC plus a PI other than dar-
unavir, with or without ritonavir. All patients taking dar-
unavir (n = 151) were taking the drug in combination with
ritonavir as a boosting agent (DRV/r). The majority (74 %,
n = 389) of patients taking ABC/3TC with a non-dar-
unavir PI received atazanavir (ritonavir-boosted in 67 %,
n = 261). Patients also took ABC/3TC with lopinavir/r
(14 %, n = 75) and fosamprenavir (8 %, n = 41). Less
common (\2 %) regimens included ABC/3TC with nelfi-
navir, saquinavir, or indinavir.
3.2 Baseline Characteristics
Patients taking ABC/3TC ? DRV/r were similar to those
taking ABC/3TC with other PIs in most baseline demo-
graphic and clinical features (Table 1). In this cohort,
patients did not initiate regimens containing DRV/r until
2007, with frequency of this drug combination increasing
over the study period. Conversely, patients were less fre-
quently prescribed ABC/3TC plus other PIs in the later
years of the study period.
Patients receiving DRV/r were more likely to have an
active hepatitis B or C infection at the time they initiated
the regimen than patients initiating regimens with other PIs
(2.6 vs. 0.6 %; p = 0.03). Patients starting ABC/
3TC ? DRV/r have comparable CD4 counts (median
[IQR] cells/mm3: 333 [193–565] vs. 397 [213–621];
p = 0.18) and viral loads (median [IQR] log10 copies/mL:
1.9 [1.5–3.2] vs. 1.7 [1.7–3.1]; p = 0.93). About half of the
patients taking both DRV and non-DRV-based regimens
(46 and 52 %; p = 0.2) were suppressed below 50 copies/
mL at the time of regimen initiation.
3.3 Treatment and Treatment Response
As a result of DRV prescribed in the later years of the study
period, patients taking ABC/3TC ? DRV/r tended to have
less follow-up while on DRV/r than patients taking ABC/
3TC plus a non-DRV PI (median: 14 vs. 17 months;
p = 0.04), as well as less follow-up time overall (median:
33 vs. 68 months; p\ 0.001).
Patients receiving DRV-containing regimens were less
likely to achieve an undetectable viral load both while
taking the regimen (64 vs. 72 %; p = 0.04) and during
their total duration of follow-up (74 vs. 86 %; p\ 0.001)
(Table 2). The lowest viral load achieved between baseline
and the end of the regimen was similar between the two




Received treatment with ARVs: 51,036
Took ABC/3TC at any time: 12,542 
Took other ARVs before  ABC/3TC: 6,173
ABC/3TC started 2005 or later: 4,128
ABC/3TC started after 1st OPERA visit : 3,770
Had baseline/follow-up lab data: 2,122





Fig. 1 Selection of eligible patients for primary analysis. ABC/3TC
abacavir/lamivudine, ARVs antiretrovirals, DRV/r darunavir boosted
with ritonavir, OPERA Observational Pharmaco-Epidemiology
Research and Analysis, PI protease Inhibitor
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treatment groups, as was the lowest viral load achieved
prior to the end of follow-up. Gains between baseline and
highest CD4 measured while on the regimen of interest
were similar between PI groups (median [IQR] cells/mm3:
106 [20–245] vs. 118 [19–271]; p = 0.59), but over all of
follow-up, patients taking ABC/3TC with a non-darunavir
PI experienced higher CD4 counts (median [IQR] cells/
mm3: 696 [435–930] vs. 570 [328–842]; p = 0.02) and
greater CD4 lymphocyte gains from baseline (median
[IQR] cells/mm3: 217 [87–389] vs. 166 [70–312];
p = 0.04).
In unadjusted models, patients taking ABC/
3TC ? DRV/r appeared to be significantly less likely to
achieve an undetectable viral load, both while taking the
regimen (OR [95 % CI]: 0.67 [0.45–0.98]) and for the
duration of follow-up (0.46 [0.30, 0.72]) (Table 3). After
Table 1 Baseline characteristics of antiretroviral therapy-experienced patients initiating their first regimen of either ABC/3TC ? DRV/r or
ABC/3TC ? PI (not DRV)a
Characteristic ABC/3TC ? DRV/rb (n = 151)
[n (%)d]
ABC/3TC without DRV/rc (n = 525)
[n (%)d]
p value
Male sex 124 (82.1) 415 (79.0) 0.41
Age, years [median (IQR)] 46.8 (39.6–53.4) 45.6 (39.1–52.8) 0.61
African American race
African American 65 (43.0) 212 (40.4) 0.56
Non-African American 86 (57.0) 313 (59.6)
Ethnicity
Hispanic 20 (13.2) 67 (12.8) 0.88
Non-hispanic 131 (86.8) 458 (87.2)
AIDS-defining event at or before
baseline
16 (11.3) 64 (12.2) 0.59
CD4 count at baseline
\250 cells/mm3 51 (33.8) 156 (29.7) 0.34
C250 cells/mm3 100 (66.2) 369 (70.3)
CD4 count, cells/mm3 [median (IQR)] 333 (193–565) 397 (213–621) 0.18
HIV viral load at baseline
\200 copies/mL 89 (58.9) 348 (66.3) 0.10
C200 copies/mL 62 (41.1) 177 (33.7)
Log10 copies/mL [median (IQR)] 1.9 (1.5–3.2) 1.7 (1.7–3.1) 0.93
Hepatitis B or C co-infection at baseline
Yes 4 (2.6) 3 (0.6) 0.03
No 147 (97.4) 522 (99.4)
Year baseline regimen started
2005 0 (0.0) 50 (9.5) \0.0001
2006 0 (0.0) 67 (12.8)
2007 5 (3.3) 55 (10.5)
2008 11 (7.3) 62 (11.8)
2009 22 (14.6) 72 (13.7)
2010 18 (11.9) 63 (12.0)
2011 14 (9.3) 55 (10.5)
2012 18 (11.9) 41 (7.8)
2013 30 (19.9) 33 (6.3)
2014 30 (19.9) 23 (4.4)
2015 3 (2.0) 4 (0.8)
3TC lamivudine, ABC abacavir, DRV darunavir, IQR interquartile range, PI protease inhibitor, r ritonavir
a Includes only patients that had baseline CD4, baseline viral load, and at least one viral load measurement during follow-up on the regimen of
interest
b Regimen of ABC, 3TC, and DRV boosted with r
c Regimen of ABC, 3TC, and a PI other than DRV
d Unless otherwise indicated
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adjusting for baseline viral load, CD4 count, and year of
regimen initiation, there were no statistically significant
differences in achieving an undetectable viral load by PI
given with ABC/3TC, either while taking the regimen
(darunavir compared with non-darunavir during regimen:
OR [95 % CI]: 0.84 [0.53–1.34]), or during the duration of
follow-up (OR [95 % CI]: 0.82 [0.48–1.40]).
3.4 Sensitivity Analyses
Analyses attempting to balance the follow-up time between
treatment groups (by limiting the population to those with
at least 12 months of follow-up after baseline and limiting
the population to those initiating a regimen of interest in
2009 or later) produced similar crude effect estimates to the
primary analysis (Table 3). The ORs from multivariable
models were closer to null than the primary analysis, and
indicated no differences in achieving undetectable viral
loads between treatment groups.
Defining viral load suppression as fewer than
400 copies/mL rather than below detectable limits also
resulted in adjusted effect estimates close to null, but with
somewhat less precision than the results of the primary
analysis. When stratified by viral load at baseline, patients
with higher viral loads appear to be less likely to achieve
viral suppression during follow-up on the regimen and
overall than patients with a lower baseline viral loads.
4 Discussion
To our knowledge, this is the first study, interventional or
observational, comparing the effectiveness of darunavir
with other PIs when taken in combination specifically with
Table 2 Virologic and immunologic response following treatment regimens of interest (ABC/3TC ? DRV/r or ABC ? 3TC ? PI [not DRV/r])
Treatment outcomes ABC/3TC ?
DRV/ra (n = 151)
[n (%) or median
(IQR)]
ABC/3TC without
DRV/rb (n = 525)
[n (%) or median (IQR)]
p value
On therapy: measured between baseline and discontinuation of regimen
Viral load
Achieved undetectable viral loadc 96 (63.6) 380 (72.4) 0.04
Lowest viral load measured (copies/mL) 19 (19–110) 47 (19–50) 0.09
Change from baseline viral load to lowest viral load measured (copies/mL) -23 (-601 to 0) -23 (-381 to 0) 0.72
CD4
Highest CD4 count measured (cells/mm3) 482 (262–798) 585 (324–823) 0.15
Change from baseline CD4 count to highest CD4 count measured (cells/mm3) 106 (20–245) 118 (19–271) 0.59
Intent-to-treat: measured between baseline and last date of follow-up
Viral load
Achieved undetectable viral loadc 112 (74.2) 452 (86.1) 0.0005
Lowest viral load measured (copies/mL) 19 (19–40) 19 (19–47) 0.74
Change from baseline viral load to lowest viral load measured (copies/mL) -28 (-901 to 0) -30 (-813 to -1) 0.58
CD4
Highest CD4 count measured (cells/mm3) 570 (328–842) 696 (435–930) 0.018
Change from baseline CD4 count to highest CD4 count measured (cells/mm3) 166 (70–312) 217 (87–389) 0.04
On therapy
Number of CD4 count measurements 4 (3–8) 5 (3–9) 0.09
Number of viral load measurements 4 (3–7) 5 (3–9) 0.18
Months of follow-up 13.7 (7.6–22.9) 17.3 (6.9–34.9) 0.04
Intent-to-treat
Number of CD4 count measurements 7 (3–14) 12 (6–20) \0.0001
Number of viral load measurements 7 (3–13) 11 (6–18) \0.0001
Months of follow-up 33.1 (17.1–63.5) 68.1 (43.9–94.7) \0.0001
3TC lamivudine, ABC abacavir, DRV darunavir, IQR interquartile range, PI protease inhibitor, r ritonavir
a Regimen of ABC, 3TC, and DRV boosted with r
b Regimen of ABC, 3TC, and a PI other than DRV
c Suppression of viral load to undetectable limit is the primary outcome of interest for this study. Undetectable measured as below assay limit
(range\20 to\75 copies/mL)
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an ABC/3TC NRTI backbone. The results of our multi-
variable regression models suggested no statistically sig-
nificant differences in achieving viral load suppression
between treatment-experienced patients receiving a regi-
men of ABC/3TC ? DRV/r and those receiving ABC/3TC
with a different PI (boosted or unboosted).
A meta-analysis conducted by Berhan and Berhan [5]
looked at published evidence from randomized controlled
studies of virologic response in treatment-experienced
patients receiving DRV/r. Change in viral load was mea-
sured relative to regimens containing an investigator-se-
lected boosted PI. Ten studies were identified comparing
the efficacy of DRV/r with another PI. Patients taking
DRV/r (OR [95 % CI]: 4.7 [2.7–7.9]) were significantly
more likely to achieve viral load suppression (\50 copies/
mL) than patients taking ritonavir-boosted comparator PIs.
However, the backbone components of these PI-based
regimens were not taken into account for this analysis.
Reviewing these studies individually, none separately
evaluated the different NRTI backbones, and several
excluded use of abacavir altogether [8–10, 15–22].
There are few other studies of the combination of ABC/
3TC ? DRV/r, with most analyzing a small number of
patients, limiting the ability to detect a statistical difference
between treatment groups. Prior studies, however, have
shown comparable efficacies with two other NRTI/PI
combinations and none have indicated inferiority with
regimens containing other PIs. Some of the existing data






Achieved undetectable viral loadb during baseline regimen 0.67 (0.45–0.98) 0.84 (0.53–1.34)
Achieved undetectable viral load between starting baseline regimen and last date
of follow-up
0.46 (0.30–0.72) 0.82 (0.48–1.40)
Sensitivity analyses
Balancing follow-up time between treatment groups
Patients with at least 12 months of follow-up
Achieved undetectable viral load during baseline regimen 0.77 (0.48–1.22) 0.91 (0.54–1.51)
Achieved undetectable viral load between starting baseline regimen and last
date of follow-up
0.51 (0.28–0.91) 0.55 (0.30–1.03)
Patients starting regimen 2009 or later
Achieved undetectable viral load during baseline regimen 0.66 (0.42–1.03) 0.91 (0.53–1.55)
Achieved undetectable viral load between starting baseline regimen and last
date of follow-up
0.53 (0.32–0.87) 0.99 (0.53–1.87)
Alternative definition of effectiveness
Achieved suppressed viral load (\400 copies/mL)
Achieved suppressed viral load during baseline regimen 0.83 (0.50–1.38) 0.95 (0.54–1.66)
Achieved suppressed viral load between starting baseline regimen and last
date of follow-up
0.51 (0.26–0.97) 0.98 (0.45–2.12)
Accounting for baseline viral load
Baseline viral load[200 copies/mL
Achieved undetectable viral load during baseline regimen 0.67 (0.37–1.21) 0.97 (0.49–1.93)
Achieved undetectable viral load between starting baseline regimen and last
date of follow-up
0.42 (0.23–0.75) 0.88 (0.44–1.76)
Baseline viral load B200 copies/mL
Achieved undetectable viral load during baseline regimen 0.78 (0.42–1.45) 1.10 (0.54–2.23)
Achieved undetectable viral load between starting baseline regimen and last
date of follow-up
0.65 (0.28–1.52) 1.34 (0.49–3.66)
CI confidence interval, OR odds ratio
a All models compare a regimen of abacavir/lamivudine and darunavir/ritonavir with a regimen of abacavir/lamivudine and a protease inhibitor
besides darunavir/ritonavir (reference)
b Suppression of viral load to undetectable limit is the primary outcome of interest for this study. Undetectable measured as below assay limit
(range\20 to\75 copies/mL)
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come from single-arm trials or from observational cohorts
with no comparison group, making it difficult to evaluate
the ABC/3TC ? DRV/r regimen against the effectiveness
of other drug combinations [12, 14, 15, 23].
In this cohort, observed inequalities in viral load sup-
pression to undetectable levels, both in frequency data and
in unadjusted logistic regression models, are partially
attributable to differences in potential follow-up time
between the two treatment groups. DRV/r trended towards
wider use with ABC/3TC each year of the study period.
With other PIs more frequently started in the earlier years
of the study period, patients taking darunavir-containing
regimens had shorter median follow-up durations, both on
the regimen of interest and for the total duration of follow-
up. Shorter follow-up not only results in less time for viral
load to respond to treatment, but also fewer potential
opportunities for testing. While the median number of viral
load assessments was comparable while receiving the ini-
tial ABC/3TC ? PI regimen (darunavir vs. non-darunavir
median [IQR] viral load laboratory values: 4 [3–8] vs. 5
[3–9]; p = 0.09), the large disparities in total follow-up
time resulted in far more viral load assessments for the
intent-to-treat analysis in the non-darunavir PI treatment
group (7 [3–14] vs. 12 [6–20]; p\ 0.0001).
In a sensitivity analysis restricted to patients with a least
12 months of follow-up, the disparity in follow-up time
while taking the regimen of interest was resolved, and the
proportion of patients on the DRV/r regimen achieved an
undetectable viral load was comparable with patients on
other PI regimens (70 vs. 75 %; p = 0.25). Given the
larger imbalance in months of follow-up for the intent-to-
treat analysis, patients initiating on a non-darunavir PI
regimen were still followed for a significantly longer per-
iod overall (45 vs. 69 months; p\ 0.0001) and were still
more likely to achieve viral load suppression than patients
initiating follow-up on ABC/3TC ? DRV/r. Adjusting for
calendar year of regimen initiation, among other patient
characteristics, in the multivariable logistic regression
models for the primary analysis also partially accounted for
the trend towards greater DRV/r use in the later study
years, with adjusted models showing no statistical differ-
ences in achieving an undetectable viral load.
In addition to differences in potential time to accumulate
more viral load laboratory values, the more frequent use of
DRV/r in later years of the study period could have
impacted testing in other ways, with trends towards less
frequent viral load monitoring, particularly among patients
who seem to be responding well to treatment. Furthermore,
darunavir is a potent PI with a superior resistance profile to
first-generation PIs. If clinicians perceived patients on
DRV/r as less likely to experience treatment failure, this
could be reflected in less frequent viral load evaluations.
When given equal time and opportunity to show treatment
success, DRV/r appears to be comparable with other PIs in
their ability to suppress viral loads to undetectable levels
when combined with ABC/3TC.
Patients with a wide variety of prior treatment experi-
ences and clinical characteristics at baseline were eligible
to enter the analysis cohort, and for the primary aim of this
study were analyzed as a single group, compared only by
the PI taken with ABC/3TC. The variability in clinical
characteristics was mostly comparable between the two
treatment groups. Patients receiving ABC/3TC with DRV/r
or other PIs had similar prior experience on ART before
starting their initial ABC/3TC regimen with a PI (DRV/r
vs. non-darunavir PI, time on ART at baseline [IQR]:
1.4 years [0.4–3.8] vs. 1.5 years [0.6–3.9]; p = 0.4).
Baseline viral load was highly variable among all patients,
regardless of treatment group. About half of patients,
whether starting ABC/3TC with DRV/r or another PI, had a
viral load of\50 copies/mL at baseline, while another 14
and 17 %, respectively (p = 0.4), had a viral load[20,000
copies/mL at baseline.
Not accounting for the initial viral load limits interpre-
tation of the results from the primary analysis. To account
for baseline viral load, sensitivity analyses were performed
that were restricted to either patients with a viral load (1) at
or below or (2) above a threshold indicating virologic
control (200 copies/mL) at the time of switch. For patients
with a baseline viral load B200 copies/mL at baseline,
crude and adjusted models both indicated no difference in
ability to achieve an undetectable viral load between
patients taking ABC/3TC with DRV/r and those taking
ABC/3TC with another PI. For patients with a baseline
viral load [200 copies/mL, the crude model for all of
follow-up indicated reduced odds of suppression among
those taking DRV/r. The multivariable model for this
subgroup, which included an adjustment for time (year of
initiation), indicated no significant differences in odds of
achieving an undetectable viral load. This suggests that for
patients starting out with higher viral loads, the amount of
time available to reach undetectable levels of viremia is
more critical than for those starting with a low viral load.
While not covered in this analysis, the variability in
baseline viral loads suggest that treatment-experienced
patients often switched to a backbone of ABC/3TC with a
PI for reasons beyond better virologic control, including
issues of tolerability and adherence. While darunavir is
considered to have favorable tolerability compared with
other PIs, patients receiving DRV were not significantly
more likely to switch while virologically controlled. This
suggests that the perceived benefit, whether for better
treatment tolerance or simplified regimen, may be in the
change of NRTI backbone, as all patients were taking
ABC/3TC for the first time in their treatment history. This
analysis could be enhanced by examining adverse event
58 P. Lackey et al.
data, to assess both differences in indicators for switch to
an ABC/3TC ? PI regimen as well as to compare tolera-
bility as a factor in treatment success between patients
taking ABC/3TC ? DRV/r and ABC/3TC plus a non-
darunavir PI.
5 Conclusion
The results of this study suggest that in clinical practice in
the USA, no difference was observed in multivariable
logistic regression analysis comparing the use of ABC/
3TC ? DRV/r versus ABC/3TC plus another PI (non-
DRV/r). Additionally, patients receiving DRV/r with ABC/
3TC were able to achieve equivalent gains in raising the
CD4 cell count and lowering viral load compared with
those taking other PIs with ABC/3TC.
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